TGFBR2 and lymphoma: Consistent with the predicted ligand–receptor signalling, TGFBR2 knockdown in CD4+ T cells increased HBx‐overexpressing lymphoma cell apoptosis, while reducing CD4+ T cell apoptosis and enhancing proliferation and effector cytokine secretion (Figure S8A–E).